Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 1
1986 1
1992 1
1997 1
2003 1
2006 2
2008 2
2009 3
2011 1
2012 2
2014 1
2015 2
2018 1
2019 1
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
Long-term use of ticagrelor in patients with prior myocardial infarction.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Bonaca MP, et al. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. N Engl J Med. 2015. PMID: 25773268 Free article. Clinical Trial.
Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Jammula S, Katz-Summercorn AC, Li X, Linossi C, Smyth E, Killcoyne S, Biasci D, Subash VV, Abbas S, Blasko A, Devonshire G, Grantham A, Wronowski F, O'Donovan M, Grehan N, Eldridge MD, Tavaré S; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) consortium, Fitzgerald RC. Jammula S, et al. Gastroenterology. 2020 May;158(6):1682-1697.e1. doi: 10.1053/j.gastro.2020.01.044. Epub 2020 Feb 4. Gastroenterology. 2020. PMID: 32032585 Free PMC article.
BACKGROUND & AIMS: Esophageal adenocarcinomas (EACs) are heterogeneous and often preceded by Barrett's esophagus (BE). Many genomic changes have been associated with development of BE and EAC, but little is known about epigenetic alterations. ...
BACKGROUND & AIMS: Esophageal adenocarcinomas (EACs) are heterogeneous and often preceded by Barrett's esophagus (BE). Man …
Anaesthetic depth and complications after major surgery: an international, randomised controlled trial.
Short TG, Campbell D, Frampton C, Chan MTV, Myles PS, Corcoran TB, Sessler DI, Mills GH, Cata JP, Painter T, Byrne K, Han R, Chu MHM, McAllister DJ, Leslie K; Australian and New Zealand College of Anaesthetists Clinical Trials Network; Balanced Anaesthesia Study Group. Short TG, et al. Lancet. 2019 Nov 23;394(10212):1907-1914. doi: 10.1016/S0140-6736(19)32315-3. Epub 2019 Oct 20. Lancet. 2019. PMID: 31645286 Clinical Trial.
Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators. Morrow DA, et al. N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24. N Engl J Med. 2012. PMID: 22443427 Free article. Clinical Trial.
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial.
Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm CJ, O'Byrne PM; START Investigators Group. Pauwels RA, et al. Lancet. 2003 Mar 29;361(9363):1071-6. doi: 10.1016/S0140-6736(03)12891-7. Lancet. 2003. PMID: 12672309 Clinical Trial.
Compared with placebo, budesonide increased postbronchodilator forced expiratory volume in 1 s (FEV1) from baseline by 1.48% (p<0.0001) after 1 year and by 0.88% (p=0.0005) after 3 years (expressed as percent of the predicted value). ...
Compared with placebo, budesonide increased postbronchodilator forced expiratory volume in 1 s (FEV1) from baseline by 1.48% (p<0. …
TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.
Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, Forman D, Wild CP. Murray L, et al. Among authors: scott m. Gut. 2006 Oct;55(10):1390-7. doi: 10.1136/gut.2005.083295. Epub 2006 May 8. Gut. 2006. PMID: 16682429 Free PMC article.
METHODS: A case control study was conducted nested within a large unselected population based cohort of Barrett's patients. Incident oesophageal malignancies and high grade dysplasias were identified. ...Additional biomarkers are required which when combined with TP …
METHODS: A case control study was conducted nested within a large unselected population based cohort of Barrett's patients. In …
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma.
Ross-Innes CS, Becq J, Warren A, Cheetham RK, Northen H, O'Donovan M, Malhotra S, di Pietro M, Ivakhno S, He M, Weaver JMJ, Lynch AG, Kingsbury Z, Ross M, Humphray S, Bentley D, Fitzgerald RC. Ross-Innes CS, et al. Nat Genet. 2015 Sep;47(9):1038-1046. doi: 10.1038/ng.3357. Epub 2015 Jul 20. Nat Genet. 2015. PMID: 26192915 Free PMC article.
The molecular genetic relationship between esophageal adenocarcinoma (EAC) and its precursor lesion, Barrett's esophagus, is poorly understood. Using whole-genome sequencing on 23 paired Barrett's esophagus and EAC samples, together with one in-depth …
The molecular genetic relationship between esophageal adenocarcinoma (EAC) and its precursor lesion, Barrett's esophagus, is p …
Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts.
Sawas T, Killcoyne S, Iyer PG, Wang KK, Smyrk TC, Kisiel JB, Qin Y, Ahlquist DA, Rustgi AK, Costa RJ, Gerstung M, Fitzgerald RC, Katzka DA; OCCAMS Consortium. Sawas T, et al. Gastroenterology. 2018 Dec;155(6):1720-1728.e4. doi: 10.1053/j.gastro.2018.08.036. Epub 2018 Aug 27. Gastroenterology. 2018. PMID: 30165050 Free PMC article.
We compared survival of patients with prevalent EAC with and without synchronous Barrett esophagus (BE) with intestinal metaplasia (IM) at the time of EAC diagnosis. ...
We compared survival of patients with prevalent EAC with and without synchronous Barrett esophagus (BE) with intestinal metaplasia (I …
Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.
Weaver JMJ, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong CJ, Lao-Sirieix P, Dunning MJ, Smith L, Smith ML, Anderson CL, Carvalho B, O'Donovan M, Underwood TJ, May AP, Grehan N, Hardwick R, Davies J, Oloumi A, Aparicio S, Caldas C, Eldridge MD, Edwards PAW, Rosenfeld N, Tavaré S, Fitzgerald RC; OCCAMS consortium. Weaver JMJ, et al. Nat Genet. 2014 Aug;46(8):837-843. doi: 10.1038/ng.3013. Epub 2014 Jun 22. Nat Genet. 2014. PMID: 24952744 Free PMC article.
Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains unclear. The gradual progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) provides an ideal model t …
Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains uncle …
Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
Duffey MO, Vos TJ, Adams R, Alley J, Anthony J, Barrett C, Bharathan I, Bowman D, Bump NJ, Chau R, Cullis C, Driscoll DL, Elder A, Forsyth N, Frazer J, Guo J, Guo L, Hyer ML, Janowick D, Kulkarni B, Lai SJ, Lasky K, Li G, Li J, Liao D, Little J, Peng B, Qian MG, Reynolds DJ, Rezaei M, Scott MP, Sells TB, Shinde V, Shi QJ, Sintchak MD, Soucy F, Sprott KT, Stroud SG, Nestor M, Visiers I, Weatherhead G, Ye Y, D'Amore N. Duffey MO, et al. Among authors: scott mp. J Med Chem. 2012 Jan 12;55(1):197-208. doi: 10.1021/jm2011172. Epub 2011 Dec 5. J Med Chem. 2012. PMID: 22070629
23 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page